Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,666,391
  • Shares Outstanding, K 46,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -270,120 K
  • 36-Month Beta 2.92
  • Price/Sales 62.96
  • Price/Cash Flow N/A
  • Price/Book 5.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -2.41
  • Number of Estimates 14
  • High Estimate -2.02
  • Low Estimate -2.68
  • Prior Year -1.97
  • Growth Rate Est. (year over year) -22.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.25 +4.72%
on 10/11/18
149.26 -17.04%
on 09/21/18
-23.13 (-15.74%)
since 09/18/18
3-Month
118.25 +4.72%
on 10/11/18
172.00 -28.01%
on 07/20/18
-44.18 (-26.30%)
since 07/18/18
52-Week
59.57 +107.87%
on 10/25/17
195.97 -36.81%
on 01/31/18
+60.99 (+97.06%)
since 10/18/17

Most Recent Stories

More News
Karuna Appoints Jeff Jonas, M.D., to Board of Directors

Karuna Pharmaceuticals, Inc. ("Karuna"), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment,...

SAGE : 123.83 (+1.97%)
21.0% Return Seen to Date on SmarTrend Sage Therapeutic Call (SAGE)

SmarTrend identified a Downtrend for Sage Therapeutic (NASDAQ:SAGE) on September 11th, 2018 at $153.65. In approximately 1 month, Sage Therapeutic has returned 20.96% as of today's recent price of $121.45....

SAGE : 123.83 (+1.97%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics(NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 123.83 (+1.97%)
Watch for Sage Therapeutic to Potentially Rebound After Falling 2.39% Yesterday

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $139.07 to a high of $143.85. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of...

SAGE : 123.83 (+1.97%)
After Yesterday's Decline of 1.22%, Sage Therapeutic Offers Investors Better Value

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $144.00 to a high of $148.73. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of...

SAGE : 123.83 (+1.97%)
Sage Therapeutic Falls 2.04% on Heavy Volume: Watch For Potential Rebound

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $157.12 to a high of $161.96. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of...

SAGE : 123.83 (+1.97%)
Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

Sage Therapeutics(NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

MS : 46.03 (-2.46%)
SAGE : 123.83 (+1.97%)
Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression

--Treatment response was durable over the follow-up period, across three placebo-controlled trials

ITDD : 0.0001 (unch)
SAGE : 123.83 (+1.97%)
Today's Research Reports on Trending Tickers: Sage Therapeutics and CEL-SCI

NEW YORK, NY / ACCESSWIRE / August 22, 2018 / U.S. markets continue to edge higher on Tuesday as optimism over trade talks and upbeat earnings pushed equities into the green. Additionally, the Federal...

SAGE : 123.83 (+1.97%)
After Yesterday's Decline of 1.53%, Sage Therapeutic Offers Investors Better Value

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $139.19 to a high of $155.57. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of...

SAGE : 123.83 (+1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SAGE with:

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

2nd Resistance Point 126.92
1st Resistance Point 125.37
Last Price 123.83
1st Support Level 121.45
2nd Support Level 119.08

See More

52-Week High 195.97
Fibonacci 61.8% 143.87
Fibonacci 50% 127.77
Last Price 123.83
Fibonacci 38.2% 111.67
52-Week Low 59.57

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar